Consensus NewAmsterdam Pharma Company N.V. Börse Stuttgart

Stocks

KH6

NL00150012L7

Biotechnology & Medical Research

Market Closed - Börse Stuttgart 15:55:27 2026-08-28 EDT			5-day change	1st Jan Change
22.13 ^EUR	-3.74%		-7.09%	-24.73%

08-26	NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026	CI
08-14	Newamsterdam Pharma Company N.V. Announces Executive Changes	CI

Evolution of the Average Target: NewAmsterdam Pharma Company N.V.

Evolution of the Target Price: NewAmsterdam Pharma Company N.V.

Changes in Analyst Recommendations: NewAmsterdam Pharma Company N.V.

7ff8c8785.SLMlhfo5QmbAgzzxH7LeSB7-YgoNqKat-8JzD4I8sJ4.Hd0W981fBQqU60a3bNuuG3-ZBk1Cxuj9vPQYXft2gPgB6U7Nm3QwCJLcSw~fe3ca59743555936daedfdc5ad42c34c

Analysts' recommendations: NewAmsterdam Pharma Company N.V.

08-06	RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating	MT
07-21	BMO Capital Initiates NewAmsterdam Pharma at Outperform With $58 Price Target	MT
06-30	NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says	MT
06-30	RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk	MT
03-19	Truist Initiates NewAmsterdam Pharma at Buy With $57 Price Target	MT
01-21	RBC Raises Price Target on NewAmsterdam Pharma to $47 From $44, Keeps Outperform, Speculative Risk	MT
11-06	RBC Raises Price Target on NewAmsterdam Pharma to $44 From $39, Keeps Outperform, Speculative Risk	MT
25-08-25	Wells Fargo Initiates Coverage on NewAmsterdam Pharma With Overweight Rating, $45 Price Target	MT
25-08-07	RBC Lifts Price Target on NewAmsterdam Pharma to $39 From $38, Keeps Outperform, Speculative Risk	MT
25-07-17	Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target	MT
25-06-17	Citigroup Initiates NewAmsterdam Pharma at Buy With $42 Price Target	MT
25-06-10	Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target	MT
25-06-04	Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target	MT
24-12-30	HC Wainwright Initiates NewAmsterdam Pharma at Buy With $48 Price Target	MT
24-08-28	Needham Initiates NewAmsterdam Pharma at Buy With $36 Price Target	MT
24-05-15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
24-03-14	Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	MT
24-02-29	RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	MT
24-01-18	Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target	MT
23-10-30	RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target	MT
23-04-03	Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating	MT
23-01-06	Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target	MT
22-12-20	SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target	MT
22-12-20	SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target	MT
22-12-19	William Blair Starts NewAmsterdam Pharma at Outperform	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+16.85%
	ARGENX SE					+9.86%
	BIONTECH SE					+17.86%
	INSMED INCORPORATED					+68.87%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.81%
	PHARMAESSENTIA CORPORATION					-13.15%
	GENMAB A/S					+12.58%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+20.2%
	EXELIXIS, INC.					-2.66%
	Average					+15.69%
	Weighted average by Cap.					+16.34%